[1]Jha V, Garcia-Garcia G, Iseki K, et al.Chronic kidney disease: global dimension and perspectives[J].Lancet, 2013, 382(9888):260-72
[2]Zhang L, Zhao M H, Zuo L, et al.China Kidney Disease Network (CK-NET) 2015 Annual Data Report[J].Kidney Int Suppl, 2019, 9(1):e1-e81
[3] Kim H W, Kim S H, Kim Y O, et al.Comparison of the impact of high-flux dialysis on mortality in hemodialysis patients with and without residual renal function[J].PLoS ONE, 2014, 9(6):e97184
[4]Bi H, Zhang M, Zhang Y, et al.Influence of high flux hemodialysis on C-reactive protein and lipids metabolism[J].Journal of Clinical Rehabilitative Tissue Engineering Research, 2010, 14(25):4689-4692
[5]Cheung A K, Agodoa L Y, Daugirdas J T, et al.Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulinThe Hemodialysis (HEMO) Study Group[J].J Am Soc Nephrol, 1999, 10(1):117-27
[6]Eknoyan G, Beck G J, Cheung A K, et al.Effect of dialysis dose and membrane flux in maintenance hemodialysis[J].N Engl J Med, 2002, 347(25):2010-9
[7]Locatelli F, Martin-Malo A, Hannedouche T, et al.Effect of membrane permeability on survival of hemodialysis patients[J].J Am Soc Nephrol, 2009, 20(3):645-54
[8]Locatelli F, Mastrangelo F, Redaelli B, et al.Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parametersThe Italian Cooperative Dialysis Study Group[J].Kidney international, 1996, 50(4):1293-1302
[9]Kuchle C, Fricke H, Held E, et al.High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis[J].Am J Nephrol, 1996, 16(6):484-8
[10]Li P K, Cheng Y L, Leung C B, et al.Effect of membrane permeability on inflammation and arterial stiffness: a randomized trial[J].Clin J Am Soc Nephrol, 2010, 5(4):652-8
[11]Asci G, Tz H, Ozkahya M, et al.The impact of membrane permeability and dialysate purity on cardiovascular outcomes[J].J Am Soc Nephrol, 2013, 24(6):1014-23
[12]Ayli M, Ayli D, Azak A, et al.The effect of high-flux hemodialysis on dialysis-associated amyloidosis[J].Ren Fail, 2005, 27(1):31-4
[13]Blankestijn P J, Vos P F, Rabelink T J, et al.High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients[J].J Am Soc Nephrol, 1995, 5(9):1703-8
[14]Chu P L, Chiu Y L, Lin J W, et al.Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance[J].Blood Purif, 2008, 26(2):213-20
[15]House A A, Wells G A, Donnelly J G, et al.Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids[J].Nephrol Dial Transplant, 2000, 15(7):1029-34
[16]Locatelli F, Andrulli S, Pecchini F, et al.Effect of high-flux dialysis on the anaemia of haemodialysis patients[J].Nephrol Dial Transplant, 2000, 15(9):1399-409
[17]Ottosson P, Attman P O, Knight C, et al.Do high-flux dialysis membranes affect renal dyslipidemia?[J].Asaio j, 2001, 47(3):229-34
[18] Goldberg I J, Kaufman A M, Lavarias V A, et al.High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease[J].Nephrol Dial Transplant, 1996, 11(suppl2):104-7
[19]Gardinali M, Calcagno A, Conciato L, et al.Complement activation in dialysis: effects on cytokines,lymphocyte activation and beta 2 microglobulin[J].Int J Artif Organs, 1994, 17(6):337-44
[20]Klemm A, Franke C, Busch M, et al.Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites[J].Clin Nephrol, 2004, 61(3):191-7
[21]班遵浦, 罗国鸿, 陈彤.高通量透析的效果及对患者生存率的影响[J].中国现代医学杂志, 2017, 27(11):125-128
[22] 陈玉琼, 王娟, 方华, et al.高通量血液透析与常规血液透析对慢性肾功能衰竭尿毒症期患者的疗效比较[J].疑难病杂志, 2015, 14(9):932-935
[23]何志红, 易建伟, 袁峰.高通量血液透析和常规血液透析对尿毒症患者血脂代谢的影响[J].实验与检验医学, 2016, 34(6):770-771
[24]兰薇, 周结学, 许凤英.高通量血液透析与常规血液透析的临床疗效比较研究[J].中国医药导刊, 2013, 15(02):262-263
[25]张以勤, 纪美玉, 刘小平.高通量血液透析与低通量血液透析的透析效果比较[J].国际泌尿系统杂志, 2010, 30(5):619-621
[26]易晔, 卢远航, 冀倩倩.高通量血液透析对糖尿病肾病透析患者氧化应激及微炎症状态的影响[J].重庆医学, 2015, 44(19):2667-2669
[27]陈伟, 崔天蕾, 谢林伸.不同血液净化方式对维持性血液透析患者微炎症状态和营养状态的影响[J].中国老年学杂志, 2015, 35(02):379-380
[28]Gejyo F, Kawaguchi Y, Hara S, et al.Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column[J].Artif Organs, 2004, 28(4):371-80
[29]Kim Y W, Park S.Confronting Practical Problems for Initiation of On-line Hemodiafiltration Therapy[J].Electrolyte Blood Press, 2016, 14(1):1-4
[30]Oruckaptan H, Karli O?uz K, I?ikay I, et al.Amyloidoma of the temporal bone and upper cervical spine; presentation of a rare clinical entity with a brief literature review[J].Turk Neurosurg, 2009, 19(2):159-62
[31]Vandenbroucke J M, Jadoul M, Maldague B, et al.Possible role of dialysis membrane characteristics in amyloid osteoarthropathy[J].Lancet, 1986, 1(8491):1210-1
[32]Zhao S, Wang Y, Mu Y, et al.Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS)[J].Atherosclerosis, 2014, 235(2):463-9
[33]Ishimitsu T, Nakano N, Sudo Y, et al.Predictive significance of blood pressure values for the incidence of cardiovascular events in chronic hemodialysis patients[J].Hypertens Res, 2008, 31(9):1703-9
[34]Mcintyre C W.Effects of hemodialysis on cardiac function[J].Kidney Int, 2009, 76(4):371-5
[35]Elshamaa M F, Sabry S, Nabih M, et al.Oxidative stress markers and C-reactive protein in pediatric patients on hemodialysis[J].Ann Nutr Metab, 2009, 55(4):309-16
[36]Locatelli F, Gauly A, Czekalski S, et al.The MPO Study: just a European HEMO Study or something very different?[J].Blood Purif, 2008, 26(1):100-4
